Skip to content

JBIO JBIO Occupancy and Related Charges

Occupancy and Related Charges at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseExpense.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's occupancy and related charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's occupancy and related charges?
JBIO (JBIO) reported occupancy and related charges of $26K in Q1 2026.
What does occupancy and related charges mean?
This represents the periodic cost recognized for the use of leased assets, such as office or laboratory space, under operating lease agreements. It reflects the ongoing overhead required to maintain physical facilities for research and development operations. Monitoring this helps assess the fixed cost burden of the company's physical infrastructure.